临床试验教会我们关于人类IgA肾病病理生理学的什么
本文综述了IgA肾病(IgAN)的病理生理机制及近期临床试验的启示。IgAN以IgA为主的系膜免疫复合物沉积为特征,约40%患者诊断后10年内进展至肾衰竭。英国罕见肾病国家登记处数据强调早期诊断和严格降蛋白尿的重要性。布地奈德靶向释放制剂、B细胞及浆细胞靶向药物、补体因子B抑制剂iptacopan等新疗法基于对发病机制的深入理解而出现。
要点
- IgAN以IgA为主或共主的系膜免疫复合物沉积为特征,约40%患者诊断后10年内发生肾衰竭。
- 英国罕见肾病国家登记处数据强调早期诊断、及时管理和严格降低蛋白尿以避免终身肾衰竭。
- 布地奈德靶向释放制剂是美国FDA批准的首个IgAN治疗,主要作用于肠道相关淋巴组织减少致病性半乳糖缺陷型IgA1产生。
核心结论
- 对IgAN病理生理学的阐明、全基因组关联研究数据及肾脏健康倡议(将蛋白尿变化确定为临床试验可接受的替代终点)已彻底改变IgAN治疗格局。
研究设计与样本
- 本文为综述,回顾当前IgAN临床试验并批判性审视其对IgAN发病机制的启示。
主要发现
- 约40%的IgAN患者诊断后10年内发生肾衰竭。
- 布地奈德靶向释放制剂被认为是首个美国FDA批准的IgAN治疗,主要作用于肠道相关淋巴组织以减少致病性半乳糖缺陷型IgA1的产生。
- B细胞和浆细胞在致病性半乳糖缺陷型IgA1及其自身抗体产生中起核心作用,正通过B细胞活化因子和增殖诱导配体细胞因子抑制剂以及CD38阳性浆细胞耗竭药物进行靶向。
- 补体因子B抑制剂iptacopan已获批,基于对替代补体级联在IgAN介导的肾小球损伤和炎症中作用的认识。
- 内皮素A受体拮抗剂等其他非免疫抑制治疗可用或正在研究中,旨在降低蛋白尿和延缓慢性肾脏病进展。
关键数值与推荐
- 肾脏健康倡议确定蛋白尿变化为临床试验可接受的替代终点。
临床怎么用
- 英国罕见肾病国家登记处数据强调需要早期诊断、及时管理和严格降低蛋白尿,以避免受影响患者终身发生肾衰竭。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunoglobulin A nephropathy (IgAN) is a primary glomerulonephritis characterized by IgA-dominant or co-dominant mesangial immune deposits seen on routine immunofluorescence staining of kidney biopsy tissue. Approximately 40% of patients develop kidney failure within 10 years of diagnosis. IgAN has a variable clinical presentation ranging from the characteristic synpharyngitic macroscopic haematuria to persistent microscopic haematuria with or without proteinuria, often accompanied by reduced kidney function if disease recognition is delayed. Recent data from the UK National Registry of Rare Kidney Diseases underscores the need for early diagnosis, prompt management and stringent proteinuria reduction to avoid kidney failure throughout an affected patient's lifetime. Until recently, there had been a paucity of disease-specific treatment options. However, elucidation of IgAN pathophysiology, data from genome-wide association studies and the Kidney Health Initiative (that identified change in proteinuria as an acceptable surrogate endpoint for clinical trials) have revolutionized the IgAN therapeutic landscape. Beyond systemic steroids, we now have a targeted-release formulation of budesonide, which is thought to act primarily on the gut-associated lymphoid tissue to reduce the production of pathogenic galactose-deficient IgA1. It was the first US Food and Drug Administration-approved IgAN treatment. B cells and plasma cells that play a central role in the production of galactose-deficient IgA1 and its autoantibody are being targeted using B cell activating factor and a proliferation-inducing ligand cytokine inhibitors as well as CD38-positive plasma cell-depleting drugs. Recognizing the role of the alternative complement cascade in IgAN-mediated glomerular injury and inflammation identified new potential therapeutic targets and ultimately led to the approval of a complement factor B inhibitor, iptacopan. Other non-immunosuppressive treatments are also available or being investigated with the aim of reducing proteinuria and slowing chronic kidney disease progression, including endothelin A receptor antagonists. In this article we review current clinical trials in IgAN and critically examine what they teach us about IgAN pathogenesis.
引用
- Konda R, Rajasekaran A, Rizk DV, et al. What do clinical trials teach us about the pathophysiology of human IgA nephropathy? Nephrol Dial Transplant. 2026. PMID: 40796290. doi:10.1093/ndt/gfaf144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。